The Economic Evolution of Durham and the Research Triangle Park

The modern economic geography of Durham, North Carolina, represents a profound, policy-driven industrial transformation that laid the groundwork for advanced technological innovation. During the late nineteenth and early twentieth centuries, Durham’s economy was overwhelmingly dependent on traditional agriculture, textile manufacturing, and tobacco processing, spearheaded by the American Tobacco Company founded by Washington Duke. Following World War II, these legacy industries began to hemorrhage market share to overseas competitors due to globalization and shifting trade agreements, resulting in a severe regional economic contraction. By the early 1950s, North Carolina’s per capita income was among the lowest in the nation, ranking forty-seventh out of the forty-eight states, which triggered a massive outmigration of university graduates seeking viable employment.

Facing this severe economic decline, state leaders, including Governor Luther Hodges and prominent business figures like Archie Davis and Romeo Guest, engineered a radical geographic and economic solution: the creation of the Research Triangle Park (RTP) in 1959. Geographically anchored by Duke University in Durham, the University of North Carolina at Chapel Hill, and North Carolina State University in Raleigh, RTP was established as a 7,000-acre dedicated research zone designed to foster collaboration between academia and private industry. Unlike other technology hubs that grew organically out of localized startup cultures, RTP was a deliberately planned innovation cluster utilizing restrictive land covenants to recruit massive multinational research and development facilities, beginning with early anchors like IBM and Burroughs-Wellcome.

This strategic pivot successfully birthed entirely new industrial sectors within Durham County. As the region transformed from a hub of manual labor into a premier destination for scientific inquiry, the application of corporate tax incentives became paramount. The United States federal government, recognizing the need to incentivize domestic innovation, codified the Credit for Increasing Research Activities under Internal Revenue Code (IRC) Section 41, alongside the deduction for research and experimental expenditures under IRC Section 174. Concurrently, the State of North Carolina historically offered its own incentives under Article 3F of the General Statutes, creating a layered, highly lucrative tax environment. The following case studies illustrate the historical emergence of five critical sectors in Durham and detail how companies within them satisfy the rigorous requirements of United States federal and North Carolina state research and development tax laws.

Industry Case Study 1: Contract Research Organizations

Durham is internationally recognized as the birthplace and the global epicenter of the Contract Research Organization industry. The genesis of this sector traces back to 1974 when Dr. Dennis Gillings, a biostatistics professor at the University of North Carolina, began providing statistical and data management consulting services to pharmaceutical companies struggling to navigate increasingly complex drug efficacy data requirements. Recognizing the massive market potential of outsourcing clinical trial management, Gillings formally incorporated Quintiles in North Carolina in 1982. The presence of top-tier medical institutions such as the Duke Clinical Research Institute, combined with the statistical talent pool generated by regional universities and homegrown analytical software firms, allowed Durham to capture a massive share of global pharmaceutical outsourcing. Following a series of acquisitions and a monumental merger with IMS Health in 2016, Quintiles evolved into IQVIA, retaining its corporate headquarters in Durham and employing tens of thousands globally. Today, Durham hosts massive operational hubs for global organizations like IQVIA, PPD, Syneos Health, and Parexel, cementing the region’s status as the world’s largest concentration of clinical research outsourcing.

Contract Research Organizations present a highly complex and heavily scrutinized profile for the IRC Section 41 federal research and development tax credit, primarily due to the stringent statutory exclusion for funded research. Under IRC Section 41(d)(4)(H), any research conducted to the extent that it is funded by a grant, contract, or another person or governmental entity is explicitly excluded from being classified as qualified research. The Internal Revenue Service aggressively audits contract research organizations to ensure they are not claiming tax credits for research where the financial risk is ultimately borne by the pharmaceutical sponsor paying for the clinical trial. To successfully claim the credit, a Durham-based contract research organization must satisfy a rigorous two-part test established by Treasury Regulations and federal case law regarding funding. First, the organization’s payment must be contingent on the success of the research, meaning the organization bears the economic risk of failure. Contracts structured on a time-and-materials basis generally fail this test, whereas fixed-price contracts often satisfy it, as the organization must absorb the cost of overruns or technical failures. Second, the organization must retain substantial rights to the research results, meaning they are legally permitted to use the proprietary know-how, algorithms, or methodologies generated during the project to perform future work for other clients.

The nuances of this funded research exclusion were recently litigated in the 2024 United States Tax Court case of System Technologies Inc. v. Commissioner, where the court denied the Internal Revenue Service’s motion for summary judgment, affirming the precedent that fixed-price contracts do inherently retain economic risk for the taxpayer performing the research. Furthermore, in Lockheed Martin Corp. v. United States, the Federal Circuit Court of Appeals expanded the substantial rights analysis, confirming that a taxpayer can retain substantial rights to the underlying research methodologies even if the client retains the rights to the final specific product. Contract research organizations in Durham meticulously structure their Master Services Agreements to ensure they retain intellectual property rights to the proprietary decentralized trial software, predictive machine learning algorithms, and patient data management systems they develop, even if the underlying pharmaceutical compound patent belongs exclusively to the drug sponsor.

Assuming the funding hurdles are cleared, the organization must then apply the statutory four-part test to its specific activities. The first requirement, the permitted purpose test, dictates that the research must be intended to develop a new or improved business component regarding its functionality, performance, reliability, or quality. The second requirement demands the elimination of technical uncertainty concerning the capability, method, or appropriateness of the design of the business component. The third requirement dictates that the research must be technological in nature, relying on hard sciences such as computer science, engineering, or biological sciences. Finally, substantially all of the activities must constitute a process of experimentation, involving the systematic evaluation of alternatives.

For example, a Durham-based contract research organization may undertake the development of a proprietary neural network designed to scrub decentralized, unstructured electronic health records to identify highly specific patient populations for a rare-disease oncology trial. The permitted purpose is the creation of a novel software component to improve trial enrollment speed and reliability. Technological uncertainty exists at the project’s onset regarding the optimal natural language processing architecture required to parse the medical data while maintaining strict HIPAA compliance. The activity relies fundamentally on computer science and advanced biostatistics. The engineering teams engage in a rigorous process of experimentation by writing initial algorithms, testing them against isolated data subsets, analyzing the false-positive rates for patient matching, and iteratively refactoring the codebase to optimize the mathematical weights until the target predictive accuracy is achieved. The wages paid to the data scientists and biostatisticians performing this experimental software development constitute highly lucrative qualified research expenses.

Industry Case Study 2: Biotechnology and Organ Bioengineering

While the initial decades of the Research Triangle Park were characterized by the recruitment of traditional chemical and electronic hardware manufacturers, the 1980s ushered in a deliberate pivot toward the biotechnology revolution. Recognizing the commercial potential of the biological sciences, the North Carolina General Assembly created the North Carolina Biotechnology Center in 1984, establishing the nation’s first state-sponsored initiative specifically designed to fund and accelerate the biotechnology sector. This institution provided vital seed capital, specialized laboratory space, and strategic networking that bridged the gap between academic discoveries at Duke and UNC and commercialization, effectively transforming Durham into a global leader in advanced biologics, genomics, and targeted therapeutics. A premier manifestation of this evolution is United Therapeutics. Founded in 1996, the company established a massive 630,000-square-foot co-headquarters campus within the Research Triangle Park. While the company generates significant revenue from traditional pulmonary hypertension pharmaceuticals, United Therapeutics has pioneered an entirely new frontier of the life sciences industry in Durham: organ bioengineering and xenotransplantation. The company is currently utilizing its advanced clinical laboratories to develop genetically modified porcine organs, including xenokidneys and xenohearts, intended for human transplantation, pushing the absolute boundaries of modern medical science.

Biotechnology companies operate at the very core of the statutory intent behind the federal research and development tax credit. For enterprises engaged in complex biological development, the costs associated with pre-clinical discovery and Food and Drug Administration Phase I, II, and III clinical trials are generally deemed eligible qualified research expenses. The Internal Revenue Service’s official Pharmaceutical Industry Research Credit Audit Technique Guide provides specific safe harbors, generally directing examiners not to challenge the qualification of activities occurring during the discovery, pre-clinical, and clinical development stages, provided the expenses are properly substantiated.

Applying the four-part test to a discipline like xenotransplantation demonstrates clear eligibility. The permitted purpose is the development of a genetically modified porcine kidney that resists hyperacute immunological rejection when transplanted into a human recipient. The research is undeniably technological in nature, relying entirely on advanced molecular biology, genetics, and immunology. Massive technological uncertainty exists regarding the exact combination of gene knockouts, such as the removal of the alpha-gal sugar, and the insertion of human transgenes required to prevent the human complement system from immediately destroying the foreign tissue. To eliminate this uncertainty, scientists engage in a highly complex process of experimentation utilizing CRISPR-Cas9 gene editing technologies. They create multiple transgenic cell lines, utilize somatic cell nuclear transfer to clone the animals, and perform extensive ex-vivo perfusion tests to evaluate immunological responses, mathematically analyzing the histopathology and iteratively refining the genetic modifications based on the assay results.

However, biotechnology firms face unique scrutiny regarding the inclusion of supply costs in their credit calculations. Under IRC Section 41(b)(2), taxpayers can claim amounts paid or incurred for supplies used in the conduct of qualified research. The definition of supplies includes tangible property, excluding land and depreciable assets, directly consumed in the experimental process. The complexities of supply costs were heavily litigated in Union Carbide Corp. v. Commissioner, a decision subsequently affirmed by the Second Circuit Court of Appeals. The court ruled that taxpayers cannot claim the costs of supplies used in process research if those supplies would have been purchased and consumed in the normal course of commercial production regardless of the research activity. Therefore, claiming supply costs for process improvements requires demonstrating that the primary purpose of the materials was for research, not routine manufacturing. For a Durham biomanufacturer developing targeted therapies or bioengineered organs, this requires meticulous, batch-level tracking. The company must implement accounting systems that definitively segregate the costs of specialized reagents, transgenic laboratory animals, and biologic media that are specifically consumed or destroyed during failed experimental assays from any materials that eventually yield a viable, commercialized product sold to the public.

Industry Case Study 3: Agricultural Technology

North Carolina possesses a deep agrarian heritage, with its historical economic foundation built upon the cultivation of tobacco and cotton. As global demand and public reception for traditional tobacco products shifted dramatically in the late twentieth century, the state successfully leveraged its generational agronomic expertise and the massive intellectual capital of North Carolina State University, a premier agricultural land-grant institution, to pivot toward the rapidly expanding field of Agricultural Technology. Durham and the broader Research Triangle region now host an agricultural biotechnology industry that generates approximately 86 billion dollars annually and employs over 7,000 highly specialized workers. The region has attracted global crop science conglomerates alongside highly disruptive startup enterprises. A prime Durham-specific example is AgBiome, an innovative company located in the Research Triangle Park that utilizes proprietary genomic platforms to discover, isolate, and develop novel microbes for use as biological fungicides and insecticides. By mapping the complex microbiome of agricultural crops, companies like AgBiome create sustainable, biological alternatives to synthetic chemical pesticides, directly addressing critical global food security and environmental challenges.

Agricultural technology inherently represents a multidisciplinary synthesis of traditional biological sciences, advanced agronomy, heavy software development, and data analytics. When claiming the federal research and development tax credit, the calculation of the historical base amount is particularly critical for venture-backed agricultural technology firms. Under IRC Section 41(c), the credit is strictly incremental; a company can only claim the credit on research spending that exceeds a historically determined baseline. This baseline is calculated by multiplying the taxpayer’s fixed-base percentage by their average annual gross receipts for the four preceding taxable years. For newly established startups in Durham that lack a long history of gross receipts, the tax code provides specialized start-up rules. These provisions assign an arbitrary initial fixed-base percentage, allowing pre-revenue companies investing heavily in capital-intensive greenhouse research to immediately monetize their qualified research expenses without being penalized for lacking historical sales data.

The application of the statutory four-part test to agricultural technology is robust. Consider a Durham-based firm developing a novel, microbe-based biological fungicide designed to protect sweet potatoes, a major North Carolina commodity, from devastating soil-borne pathogens. The permitted purpose is the formulation of a new biological product to improve agricultural yield and disease resistance. The activity is technological in nature, relying heavily on microbiology, genomics, and biochemistry. Significant uncertainty exists at the project’s inception. While the company may possess a vast, sequenced database of thousands of microbial strains, there is profound technical uncertainty regarding which specific strain will exhibit high efficacy against the targeted pathogen without causing phytotoxicity to the host plant, and further uncertainty regarding how to formulate the living microbe to ensure adequate shelf stability and field survivability. The process of experimentation involves isolating specific bacterial strains, conducting high-throughput in vitro screening assays, and subsequently executing iterative in vivo greenhouse trials. The scientists manipulate various formulation variables, such as introducing different biological surfactants and ultraviolet light protectants, rigorously measuring spore survival rates and disease suppression metrics, and systematically discarding failed prototypes until an optimal, stable biological fungicide is finalized for regulatory submission.

The financial mechanics of this research were drastically altered by the One Big Beautiful Bill Act of 2025. If this agricultural technology firm spends two million dollars in the 2025 tax year on domestic greenhouse facility leases, agronomist wages, and specialized laboratory supplies directly related to this project, the new legislation allows them to immediately deduct the full two million dollars against their taxable income under the restored provisions of IRC Section 174A. This immediate expensing provides a massive cash flow advantage over the restrictive five-year amortization schedules that were previously mandated between 2022 and 2024, freeing up capital to reinvest in local scientific talent.

Industry Case Study 4: Software Development and Information Technology

While the Research Triangle Park was successfully attracting massive hardware and mainframe computing facilities in the 1960s and 1970s, the downtown core of the City of Durham was experiencing a much different reality. Following the abandonment of the massive brick tobacco processing factories by conglomerates like the American Tobacco Company and Liggett & Myers, the downtown area faced severe urban blight and economic stagnation. However, in 2010, the Capitol Broadcasting Company initiated a monumental redevelopment project, repurposing the subterranean spaces of the historic American Tobacco Campus to launch an incubator known as the American Underground. Intentionally designed as a diverse counter-narrative to the dominant Silicon Valley model, the American Underground provided affordable coworking space, direct access to venture capital networks, and a highly collaborative community tailored for technology entrepreneurs. Dubbed the Startup Capital of the South, this redevelopment sparked an explosion of software-as-a-service, cybersecurity, and information technology enterprises within Durham. A standout success story from this ecosystem is Pendo, a software firm founded in the region in 2013 that develops sophisticated product-analytics platforms designed to help software companies optimize user experiences, rapidly scaling to serve massive enterprise clients.

Software development is heavily scrutinized by the Internal Revenue Service during tax examinations. Historically, landmark cases such as Apple Computer, Inc. v. Commissioner firmly established that software engineering activities could qualify for the research credit, provided they met the strict requirements of the four-part test under Section 41(d). However, the IRS draws a very sharp, restrictive line between software developed for commercial sale and Internal Use Software.

If a Durham-based technology startup develops a software application solely for its own general and administrative functions, such as a proprietary human resources portal or an internal financial accounting tool, it is legally classified as Internal Use Software. Under the final Treasury Regulations issued in 2016, Internal Use Software is explicitly excluded from the research credit unless the taxpayer can prove it satisfies an exceptionally rigorous, additional three-part High Threshold of Innovation test. This supplementary test requires the taxpayer to demonstrate that the software is highly innovative resulting in substantial performance improvements, that the development involves significant economic risk due to substantial technical uncertainty, and that the software is not commercially available for purchase. Because this threshold is incredibly difficult to meet, most internal administrative software projects fail to qualify. Conversely, if a company develops a cloud-based analytics platform intended to be licensed to third-party customers, or develops software that enables third parties to initiate functions or review data on the taxpayer’s system, the regulations explicitly state that it is not Internal Use Software, and the project is subject only to the standard four-part test.

When applying the four-part test to commercial software development, the permitted purpose is typically the creation of a new application programming interface or software module. The activity is technological in nature, relying on the principles of computer science and software engineering. Technical uncertainty often revolves around system architecture and performance; for instance, it may be uncertain whether a newly designed backend database structure can handle parallel processing loads required to execute complex algorithmic queries with sub-millisecond latency under peak user traffic. The process of experimentation involves software engineers writing initial code architecture, conducting rigorous stress testing under simulated load conditions, analyzing memory leak failures and processing bottlenecks, refactoring the codebase to optimize garbage collection and data routing, and re-testing the system until the latency thresholds are consistently met.

For early-stage software companies in Durham, the federal tax code offers a highly specific monetization mechanism. Qualified small businesses, defined as those with less than five million dollars in gross receipts for the taxable year and no gross receipts for any taxable year preceding the five-taxable-year period ending with the current year, can elect to apply up to 500,000 dollars of their earned research and development tax credit directly against their employer payroll tax liabilities. This payroll tax offset is a critical lifeline for pre-revenue software startups operating out of incubators like the American Underground, allowing them to realize immediate cash benefits from their engineering efforts long before they generate taxable corporate income.

Industry Case Study 5: Advanced Manufacturing and Semiconductors

North Carolina’s earliest industrial wealth was generated by the massive textile mills and furniture factories distributed throughout the Piedmont region. As late-twentieth-century globalization offshored traditional, low-skill manufacturing to countries with cheaper labor markets, Durham and the surrounding areas successfully orchestrated a transition toward advanced manufacturing. This modern iteration of manufacturing is heavily reliant on robotics, precision engineering, automated sensor systems, and advanced materials science. Today, Durham is a vital strategic node in the United States’ national security initiative to reshore semiconductor manufacturing and secure critical domestic supply chains. A premier example is Wolfspeed, a company headquartered in Durham that originally spun out of academic research conducted at North Carolina State University. Wolfspeed holds a massive global market share for the production of silicon carbide materials, which are advanced semiconductors critical for the operation of electric vehicles, 5G telecommunications networks, and clean energy infrastructure. Highlighting the region’s national importance, in early 2025, the United States Department of Commerce awarded the Semiconductor Research Corporation, headquartered in Durham, a 285 million dollar grant to establish a manufacturing institute focused on developing digital twins, which are highly accurate virtual models of physical microchips used to optimize semiconductor design and manufacturing processes.

Advanced manufacturing inherently involves the complex integration of cutting-edge materials and digital systems into physical production environments. While the research and development tax credit is highly applicable to these endeavors, the Internal Revenue Service stringently enforces the statutory boundaries separating genuine process engineering from routine commercial production and general factory floor troubleshooting. The legal requirements for manufacturing research were sharply defined in the 2021 United States Tax Court case Little Sandy Coal Co., Inc. v. Commissioner. In this case, the court denied significant tax credits because the taxpayer failed to provide sufficient quantitative documentation proving that at least 80 percent of the claimed research activities followed a structured, scientific process of experimentation, rather than just relying on general trial and error during the fabrication process. This precedent dictates that advanced manufacturers in Durham must maintain rigorous, contemporaneous engineering logs, design schematics, and testing reports to prove their activities are systematic and scientifically sound.

Furthermore, advanced manufacturers must navigate the complex Pilot Model and shrinker rules found within Treasury Regulations. If a semiconductor manufacturer builds a pilot extrusion line to test a radically new silicon carbide crystal growth process, the engineering and material costs to design, build, and evaluate that pilot line generally qualify for the credit. However, once the technical uncertainty regarding the manufacturing process is resolved and the pilot line proves capable of meeting the required specifications, the asset transitions into a state of commercial production. Any subsequent costs incurred to operate, maintain, or slightly tweak the line are strictly excluded from the credit under the Research After Commercial Production exclusion detailed in IRC Section 41(d)(4)(A).

When evaluating the development of semiconductor digital twins under the four-part test, the permitted purpose is the creation of a novel software simulation process designed to optimize the advanced packaging of heterogeneous microelectronic components. The activity relies fundamentally on solid-state physics, materials science, and computer science. Severe technological uncertainty exists regarding how thermal stress and physical pressure will affect newly designed integrated circuits during the high-speed physical assembly process, and whether the predictive mathematical algorithms governing the digital twin can accurately forecast delamination failures before they occur in the physical world. To eliminate this uncertainty, the engineering team executes a comprehensive process of experimentation. They input specific material properties and thermal dynamic variables into the software model, run hundreds of simulated manufacturing cycles, physically manufacture a prototype batch of chips, subject the physical chips to intense thermal cycling and stress testing, meticulously compare the physical failure rates to the digital twin’s theoretical predictions, and subsequently adjust the underlying mathematical algorithms to close the error gap, repeating the process until the virtual model achieves high predictive fidelity.

The Legislative and Regulatory Framework for 2026 and Beyond

Federal Capitalization Reversal: The One Big Beautiful Bill Act of 2025For decades, the standard practice allowed taxpayers to immediately deduct their research and experimental expenditures in the year they were incurred under IRC Section 174. However, the Tax Cuts and Jobs Act of 2017 fundamentally altered this landscape. Effective for tax years beginning after December 31, 2021, the law mandated that domestic research and experimental expenditures must be capitalized and amortized ratably over a five-year period, while foreign research costs were subject to a fifteen-year amortization schedule. This capitalization requirement severely degraded corporate cash flows, threatening the survival of research-intensive startups and manufacturers in Durham by forcing them to pay taxes on artificially inflated income figures.

This punitive environment was decisively corrected on July 4, 2025, when the One Big Beautiful Bill Act was signed into law. This sweeping legislation introduced a new statutory section, IRC Section 174A, which permanently restored the ability for taxpayers to fully and immediately expense their domestic research or experimental expenditures for taxable years beginning after December 31, 2024. However, the legislation maintained the punitive fifteen-year amortization requirement for all foreign research expenditures, solidifying the federal policy intent to aggressively incentivize research and development activities physically located within the United States.

The legislation also introduced highly lucrative transition rules, particularly for smaller enterprises. Small business taxpayers, defined as those with average annual gross receipts of 31 million dollars or less, are permitted to make a retroactive election to apply the immediate expensing rules to their 2022, 2023, and 2024 tax years. By filing amended returns or administrative adjustment requests before July 6, 2026, these eligible Durham startups can completely reverse the negative impacts of the prior amortization mandate, potentially unlocking massive capital refunds. Furthermore, larger corporate taxpayers who do not meet the gross receipts threshold are permitted to recover their remaining unamortized balances from the 2022 through 2024 period by electing to deduct those amounts either entirely in the 2025 tax year or ratably over the 2025 and 2026 tax years.

Administrative Scrutiny: IRS Form 6765 and Section G MandatesWhile the legislative branch provided significant relief regarding the deductibility of expenses, the Internal Revenue Service has simultaneously intensified its administrative scrutiny over the generation of the research credits themselves. Historically, taxpayers claimed the credit by reporting aggregate quantitative data on Form 6765, retaining their qualitative project documentation internally in case of a future audit. This paradigm has been dismantled.

For the 2026 tax filing season, the Internal Revenue Service finalized sweeping changes to Form 6765, introducing a highly burdensome new reporting segment known as Section G. Starting with tax years beginning after 2025, Section G mandates that taxpayers must report detailed, qualitative information for their specific business components directly on the originally filed tax return. Taxpayers are required to list their individual research projects in descending order of cost until they have accounted for 80 percent of their total qualified research expenses, up to a maximum cap of 50 distinct components. For each reported component, the taxpayer must provide the descriptive narrative detailing the scientific information sought, the exact nature of the technological uncertainty, and the specific process of experimentation undertaken, while explicitly linking the allocated wages, supply costs, and contract research expenses to that specific project.

The only taxpayers exempt from completing the mandatory Section G reporting are Qualified Small Businesses that utilize the credit exclusively to offset their payroll tax liabilities, or certain taxpayers with less than 1.5 million dollars in qualified research expenses and less than 50 million dollars in gross receipts. For the vast majority of mid-market and enterprise-level corporations operating in Durham, this administrative shift demands a fundamental overhaul of internal accounting procedures. Companies can no longer rely on retrospective, end-of-year studies to estimate their research credits; they must implement robust, real-time project tracking systems that accurately capture engineering hours, supply consumption, and qualitative scientific progress contemporaneously throughout the fiscal year. Failure to adhere to these heightened documentation standards will result in immediate claim rejections and elevated audit exposure.

Navigating the North Carolina State Tax Credit LandscapeWhile the federal incentive framework is robust and actively utilized, the state-level tax credit environment in North Carolina is currently characterized by historical expiration and legislative stagnation. For over a decade, North Carolina offered a highly effective research and development tax credit under Article 3F of Chapter 105 of the General Statutes. This credit functioned similarly to the federal code, providing a direct financial incentive for qualified North Carolina research expenses and university research expenditures. However, due to shifting state fiscal priorities, the Article 3F credit was allowed to legally expire for taxable years beginning on or after January 1, 2016. While taxpayers who generated credits prior to the expiration date are still permitted to utilize any remaining carryforwards for up to 15 years, no new research activities currently generate state-level research credits.

The absence of a dedicated state research credit represents a significant competitive disadvantage for North Carolina when compared to neighboring states actively courting high-technology manufacturing and life sciences investments. The North Carolina Department of Revenue has also demonstrated an aggressive posture regarding the auditing and clawback of other statutory tax credits. This was prominently displayed in the litigation surrounding the state’s expired renewable energy tax credit program, where the Department of Revenue attempted to assess massive clawbacks against institutional investors, including the North Carolina Farm Bureau Mutual Insurance Company, before the North Carolina Business Court ultimately ruled in favor of the taxpayers and rebuked the state’s aggressive enforcement tactics. This litigious environment underscores the necessity for flawless statutory compliance when dealing with North Carolina tax authorities.

In an attempt to rectify the competitive disadvantage caused by the expiration of Article 3F, legislators introduced Senate Bill 354, formally titled the “NC Breakthrough Act,” during the 2025-2026 legislative session. This proposed legislation aimed to reenact and comprehensively modify the state research and development tax credit, extending its operational sunset date to January 1, 2040. The bill was structurally designed to heavily incentivize collaboration with local academic institutions, proposing a massive 20 percent credit rate for North Carolina university research expenses, which would have overwhelmingly benefited the academic ecosystems surrounding Duke University and North Carolina Central University in Durham. Furthermore, the legislation introduced rigorous new corporate compliance standards, dictating that a taxpayer would only be eligible for the credit if they satisfied strict regional wage standards, provided comprehensive health insurance for all full-time employees, maintained pristine environmental compliance records devoid of serious violations, and harbored no outstanding overdue tax debts. Despite heavy lobbying from the technology and manufacturing sectors, the NC Breakthrough Act failed to advance. As of March 2026, Senate Bill 354 remains stalled in the Committee on Rules and Operations of the Senate, and the state continues to operate without a dedicated research and development tax credit.

In the absence of a direct research tax credit, corporations expanding operations within Durham must pivot toward alternative state-level economic development incentives. The primary mechanism utilized is the Job Development Investment Grant, a discretionary incentive program that provides sustained, performance-based cash grants to companies that create new high-paying jobs and inject significant capital investment into the state. Additionally, software development and digital media firms operating within hubs like the American Underground can explore eligibility under the North Carolina Interactive Digital Media Tax Credit, which rewards the creation of educational and entertainment media, though its applicability is significantly narrower than a general research credit.

Final Thoughts

The economic vitality of Durham, North Carolina, is deeply intertwined with its sustained capacity for technological innovation. From the foundational shift away from legacy tobacco manufacturing via the creation of the Research Triangle Park, to the region’s modern-day dominance in clinical contract research, xenotransplantation, agricultural technology, enterprise software, and advanced silicon carbide manufacturing, the local economy represents a diverse and powerful engine of American industrial progress.

The federal research and development tax credit under IRC Section 41, now heavily fortified by the immediate capital recovery parameters established by the 2025 One Big Beautiful Bill Act, serves as a critical financial catalyst sustaining this localized growth. The restoration of immediate domestic expensing under IRC Section 174A, combined with the retroactive amendment windows available to small businesses, provides an unprecedented opportunity for Durham-based enterprises to inject non-dilutive capital directly back into their engineering and scientific operations. However, realizing these substantial financial benefits requires absolute rigor in regulatory compliance. Corporations must continuously navigate the nuances of the statutory four-part test, meticulously defend against funded research and internal-use software exclusions, and proactively adapt their internal accounting mechanisms to satisfy the Internal Revenue Service’s heightened, mandatory qualitative reporting standards under Form 6765 Section G. By maintaining stringent, contemporaneous documentation of their scientific endeavors and skillfully leveraging available federal statutes while the state-level incentive framework remains dormant, Durham’s innovators can effectively monetize their research investments, ensuring the region remains a global leader in technology and the life sciences for decades to come.

The information in this study is current as of the date of publication, and is provided for information purposes only. Although we do our absolute best in our attempts to avoid errors, we cannot guarantee that errors are not present in this study. Please contact a Swanson Reed member of staff, or seek independent legal advice to further understand how this information applies to your circumstances.

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 6255 Towncenter Drive, Clemmons, North Carolina is less than 90 miles away from Durham and provides R&D tax credit consulting and advisory services to Durham and the surrounding areas such as: Greensboro, Winston-Salem, Fayetteville, Cary and High Point.

If you have any questions or need further assistance, please call or email our local North Carolina Partner on (984) 480-4601.
Feel free to book a quick teleconference with one of our North Carolina R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.